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ABSTRACT: There has been increasing interest and research into sarcopenia in community-dwelling older 
adults since the European Working Group on Sarcopenia in Older People (EWGSOP) agreed a consensus 
definition in 2010. Sarcopenia has been defined as loss of muscle mass with loss of muscle function (strength or 
physical performance), with measurements two Standard Deviations (SDs) below the mean of a young reference 
population. This definition does not necessitate longitudinal measurements or the absence of acute illness and 
diagnosis can be made from single measurements. We hypothesise that hospitalisation, due to a combination of 
acute inflammatory burden and muscle disuse, leads to an acute decline in muscle mass and function and may 
lead to some individuals meeting criteria for sarcopenia, acutely, based on the EWGSOP definition. This may be 
partially recoverable or may lead to increased risk of developing sarcopenia long-term. We have denoted the 
term “acute sarcopenia” to refer to acute loss of muscle mass and function associated with hospitalisation. This 
review discusses some of the current available research in this context and also identifies some of the knowledge 
gaps and potential areas for future research. 
 
Key words: sarcopenia, disuse muscle atrophy, muscle wasting disorders, acute illness, hospitalisation 
 
 
 
 
Sarcopenia refers to age-related loss of skeletal muscle 
mass and function; the term originates from Greek, 
meaning literally “loss of the flesh”. The European 
Working Group on Sarcopenia in Older People 
(EWGSOP) [1], International Working Group on 
Sarcopenia (IWGS) [2] and Asian Working Group for 
Sarcopenia (AWGS) [3] all define sarcopenia as loss of 
skeletal muscle mass and muscle function; either low 
muscle strength or low physical performance. Different 
cut-off values have been proposed dependent on the 
population, however, both the EWGSOP and AWGS have 
proposed cut-off points of measurements two Standard 
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Deviations (SDs) below the mean from a reference 
population of healthy young people [1, 3]. The EWGSOP 
defines the presence of all three criteria (low skeletal 
muscle mass, low muscle strength and low physical 
performance) as severe sarcopenia [1]. It should not be 
viewed as inevitable that all people will meet criteria for 
sarcopenia diagnosis as they age. The presence of 
sarcopenia is associated with increased risk of potentially 
detrimental outcomes including limitations upon quality 
of life [4], increased risk of falls [5] and increased 
mortality [6]. 
The presence of sarcopenia has been demonstrated to 
relate more closely to adverse outcomes than reduced 
muscle mass alone [7]. The EWGSOP has defined the 
presence of low muscle mass alone as “pre-sarcopenia” 
[1]. Another term that has been proposed is “dynapenia”, 
which refers to the presence of reduced muscle strength 
regardless of muscle mass [8]. However, the association 
between muscle mass and muscle strength is non-linear 
[9]. Sarcopenia is an all-encompassing term denoting both 
loss of muscle mass and muscle function, which has 
clinical importance and is widely used [1].  
Sarcopenia is distinct from but related to the 
diagnosis of frailty [1, 10]. This is  the  syndrome of 
multiple cumulative decline resulting in increased 
vulnerability to poor resolution of homeostasis after a 
stressor event [11]. Frailty is a measure of the observed 
heterogeneity among older people and increasing frailty is 
associated with risk of adverse outcomes such as new 
institutionalisation and mortality.  In the hospital setting, 
frailty is also associated with an increased risk of adverse 
outcomes following hospitalisation or acute illness [12–
14] and should be considered when drawing conclusions 
related to sarcopenia.  
The EWGSOP refers to the principle that both 
primary and secondary forms of sarcopenia exist; primary 
sarcopenia has no other cause other than cumulative 
insults over time associated with ageing, whereas, 
secondary sarcopenia may be disease-related or nutrition-
related [1]. The AWGS also proposes a dynamic approach 
to sarcopenia evaluation including measurement of 
changes of muscle mass and muscle function over time 
[3]. There has been significant research into the 
development of sarcopenia in community-dwelling older 
adults and associated outcomes, but there is a paucity of 
research relating to associations between sarcopenia and 
acute illness. We reason that hospitalisation for an acute 
illness or surgical procedure may be expected to 
precipitate the acute development of secondary 
sarcopenia due to an increased inflammatory burden in 
combination with muscle disuse [15]; we refer to this 
condition as “acute sarcopenia”.  
The frequency of acute sarcopenia is currently 
unknown but it is known that a higher proportion of 
individuals will meet criteria for sarcopenia at any one 
time in hospital compared to in the community. Acute 
sarcopenia is a significant problem and important area for 
future research. It is likely to be associated with increased 
financial cost secondary to increased length of stay, 
rehabilitation needs and increased social care needs [16, 
17]. It is known that bed rest leads to disuse muscle 
atrophy in healthy adults [18] and that inflammation leads 
to a heightened catabolic state [15]. We propose that the 
term acute sarcopenia should be used as an overriding 
term applying to significant changes in both muscle mass 
and muscle function associated with increased 
inflammatory burden combined with muscle disuse. The 
aim of this review is to summarise existing observations 
and hypotheses relating to acute sarcopenia observed in 
older adults during hospitalisation and how this condition 
relates to chronic sarcopenia. 
 
Sarcopenia  
 
Chronic sarcopenia: prevalence, pathology and 
outcomes 
 
The prevalence of sarcopenia amongst older community-
dwelling adults, using EWGSOP criteria, has been 
variably reported in 15 studies in economically developed 
countries as between 1-29%, in a recent systematic review 
[19]. Prevalence of sarcopenia rises with increasing age 
[20] and an increased prevalence of 32.8% amongst 
nursing home residents  has been reported [21]. The 
prevalence rate of sarcopenia amongst older hospital 
inpatients has been reported at 22.1-26.0% in four studies 
[22–25].  
The precise mechanisms that lead to sarcopenia are 
only partially understood. However, it has been 
hypothesised to be related to an accumulation of multiple 
insults over time [1]. Reduced dietary intake of protein 
[26], reduced physical activity [27], vitamin D deficiency 
[28, 29], cumulative inflammatory insults [30, 31], 
oxidative stress [32] and resistance to anabolic stimuli 
[33] have all been postulated to contribute. Mitochondrial 
dysfunction [34] and muscle denervation [35] have been 
implicated. There are currently no recognised 
histopathological features that necessitate a diagnosis. 
However, reduced muscle fibre cross-sectional area, with 
a preference for Type 2a skeletal muscle fibres [36] and 
reduced satellite cell numbers [37] are associated with 
ageing and found in sarcopenia in humans. Increased 
numbers of senescent satellite cells associated with 
reduced muscle mitochondrial function have been 
reported in aged mice [38].   
Although individual differences exist and in 
particular a high level of physical activity in adulthood 
can prevent sarcopenia [39], a decline in muscle mass 
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with age is seen in a majority of people. Importantly, the 
presence of sarcopenia is associated with increased risk of 
adverse outcomes. A prospective longitudinal study 
involving older adults in Belgium demonstrated reduced 
quality of life associated with physical function amongst 
sarcopenic individuals, although they also had a higher 
rate of frailty [4]. The relative risk of falls with the 
presence of sarcopenia has been reported as 1.82 (95% CI 
1.09-2.18) [5]. A cohort study of octogenarians conducted 
in Italy revealed excess mortality amongst sarcopenic 
individuals with a hazard ratio of 2.32 (95% CI 1.01-
5.43), after controlling for confounders. Measurements of 
impairments of Activities of Daily Living (ADLs) and 
other markers of physical frailty were controlled for, but 
frailty itself was not measured [6]. Frailty and sarcopenia 
are related conditions, but should be considered as 
distinct.  
 
Chronic sarcopenia: Inflammatory and Endocrine 
influences 
 
Inflammatory cytokines such as Interleukin 6 (IL-6) and 
Tumour Necrosis Factor Alpha (TNF-α) have been 
proposed to contribute to catabolism in skeletal muscle. 
Inflammatory cytokines activate Nuclear Factor Kappa-
light-chain-enhancer of activated B cells (NFκB) and 
Forkhead box O (FoxO) transcription factors in muscle 
resulting in proteolysis via induction of atrogenes [40]. 
Raised levels of the pro-inflammatory cytokines, IL-6 and 
TNF-α have been observed in frail and sarcopenic vs. non-
frail or non-sarcopenic cohorts [31, 40–47]. High 
Sensitivity C-Reactive Protein (hsCRP) is a non-specific 
but highly sensitive marker of inflammation. Increased 
hsCRP measurements have been demonstrated in frail 
individuals and in patients with reduced muscle function 
[46, 48–50]. The ageing group of a population based 
observational cohort study demonstrated that frail patients 
with raised hsCRP measurements were most likely to be 
admitted to hospital [51]. Elevated hsCRP levels are also 
associated with reductions in muscle strength [52, 53] and 
physical performance [52] although no consistent 
relationship with sarcopenia has been found [53].  
Endocrine and inflammatory status interact to 
modulate muscle mass. Cortisol levels have been 
demonstrated to increase slightly with age, which in turn 
is associated with muscular weakness. A cohort study of 
adults aged 65 and older in the Netherlands demonstrated 
that increased salivary but not serum concentrations of 
cortisol were associated with reductions in grip strength 
[54]. 11β-hydroxysteroid dehydrogenase type 1 (11β-
HSD1) regulates glucocorticoid exposure at the 
prereceptor level; the type 1 isoform acts as an 
oxoreductase converting cortisone to active cortisol in 
humans and can be induced by pro-inflammatory 
cytokines such as TNFα. Skeletal muscle expression of 
11β-HSD1 has recently been demonstrated to be 
negatively associated with grip strength in both men and 
women and with total lean mass in men [55]. Transgenic 
animal models have demonstrated that inactivation of 
11β-HSD1 is protective against skeletal muscle atrophy 
precipitated by the administration of exogenous 
glucocorticoids [56]. 11β-HSD1 has been demonstrated 
as a major regulator of intramyocellular protein 
metabolism, impacting upon myotube size in both animal 
and human models and expression of a number of genes 
involved in protein synthesis, growth factors and the 
ubiquitin proteasome system [57]. 
Additional endocrine regulation occurs through 
growth hormone (GH) which induces insulin-like growth 
factor 1 (IGF-1) production in the liver. Both insulin and 
IGF-1 receptors are upstream of phosphatidylinositol 3 
kinase/ protein kinase B (PI3K/AKT) pathway activation 
and can trigger protein synthesis. The PI3K/AKT pathway 
stimulates protein synthesis via activation of glycogen 
synthase kinase 3 (GSK-3) and mechanistic target of 
rapamycin (mTOR) pathways and prevents protein 
degradation via the FoxO pathway [58].  
Vitamin D has also been implicated in modulation of 
skeletal muscle mass. Muscle biopsies taken from patients 
with vitamin D deficiency have demonstrated atrophy of 
Type II muscle fibres [59]. Additionally, vitamin D 
correlates with physical performance measures, although 
this may be related to bone strengthening as well as 
muscle function [59]. Active vitamin D levels have also 
been demonstrated to correlate with muscle strength in 
healthy younger adults [60]. 
 
Associations between chronic sarcopenia and 
hospitalisation 
 
An increased risk of hospitalisation amongst individuals 
with sarcopenia compared to those without sarcopenia has 
been reported in a longitudinal study in the USA [28]. 
Similarly, the presence of frailty has been shown to 
increase the risk of hospitalisation [61]. It has been shown 
that hospitalisation itself is associated with functional 
decline. This is most marked in frail patients [12, 14]; frail 
patients admitted to hospital have longer lengths of stay 
and increased mortality [13]. Sarcopenia has also recently 
been demonstrated to be associated with increased lengths 
of stay, although, interestingly, this effect was more 
significant amongst younger individuals [62].  
Few studies have assessed sarcopenia criteria during 
the acute phase of an illness. A prospective observational 
study involving 103 older adults admitted to geriatric 
medicine wards, who had evidence of or who were felt to 
be at risk of malnutrition, demonstrated a prevalence of 
sarcopenia of 21.4%. Notably, 22.3% of patients recruited 
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to this study were unable to perform both the gait speed 
test and handgrip measurements due to acute illness. An 
association was seen between sarcopenia and increased 
mortality; further research is needed to assess the cause 
for this association [63].  
The presence of sarcopenia is associated with 
increased costs and mortality in general, vascular and liver 
transplant surgery specialties [16]. Reduced muscle mass 
was independently associated with post-operative 
complication rates and mortality amongst patients aged 80 
years and older undergoing emergency surgery in a 
Canadian study [64]. Similar findings have been found in 
studies involving older patients admitted for colorectal 
surgery [65–68]; sarcopenia is associated with adverse 
outcomes following colorectal surgery in patients aged 65 
years or older, but not in their younger counterparts [66]. 
Following colorectal surgery, older adults experience 
increased rates of post-operative infections, higher 
frequency of need for rehabilitation and longer lengths of 
stay [66]. 
 
Acute muscle wasting disorders 
 
Bed rest and disuse muscle atrophy  
 
Loss of lean leg mass during periods of bed rest in 
otherwise healthy adults has been extensively reported 
[15, 18], muscular disuse alone thus contributes to loss of 
muscle mass secondary to hospitalisation. Crucially, the 
effect of bed rest is more marked in older adults; five days 
of bed rest resulted in loss of lean leg mass and strength 
in older but not younger adults in a recent study [69]. 
Interestingly, a study involving middle-aged adults 
demonstrated that 14 days of bed rest resulted in reduction 
of cross-sectional area of muscle fibres, with a preference 
for Type 2a fibres and reduced satellite cell content [70]. 
These changes are similar to those that have been 
described with sarcopenia [36, 37], suggesting that bed 
rest may lead to an acute acceleration of this effect.  
In rodents, skeletal muscle unloading has been most 
commonly modelled using hind limb immobilisation. The 
molecular mechanisms that have been implicated in the 
development of disuse muscle atrophy are the Atrogin-1/ 
Muscle atrophy F-Box (MaFbx)/ Muscle ring finger 1 
(MuRF1) pathway, the IGF-1-AKT-mTOR pathway and 
the Myostatin pathway [71]. MaFbx and MuRF1 mRNA 
levels rise in rodent models of immobilisation; this rise is 
associated with increases in proteolysis but not inhibition 
of protein synthesis [72]. The presence of IGF-1 has been 
demonstrated to prevent proteolysis [73] and the AKT-
mTOR pathway is downregulated in rodent models of 
muscle atrophy [74]. Myostatin also inhibits protein 
synthesis via the AKT-mTOR pathway; myostatin (also 
referred to as GDF-8) knockout mice have experience 
dramatic muscle hypertrophy [75]. 
Immobilisation studies in humans have shown that 
the mechanisms involved include induction of the 
atrogenes MuRF1, Foxo3 and atrogin 1, with just 8 days 
of immobilisation leading to a 51% increase in MuRF1 
protein [76]. 
 
The acute illness effect 
 
Hypercortisolaemia has been demonstrated to exacerbate 
loss of muscle mass and muscle strength associated with 
bed rest. A controlled study involving timed 
hydrocortisone administered to healthy young men over a 
28 day period of bed rest demonstrated greater loss of lean 
leg mass compared to a bed rest only model [77]. Cortisol 
is a mediator of protein catabolism and serum levels rise 
significantly with acute illness and stressor events [78]. In 
addition, with age the serum levels of the androgen 
precursor dehydroepinadrosterone sulphate (DHEAS) 
decline, producing an increased cortisol: DHEAS ratio 
and a state of relative cortisol excess. Acute illness or 
stress such as a hip fracture will increase this imbalance 
further compromising muscle anabolism. Studies in 
elderly hip fracture patients have shown an increased 
cortisol: DHEAS ratio and this was associated with 
increased physical frailty up to 6 months after injury [79]. 
This suggests that changes in muscle mass and muscle 
function associated with hospitalisation are not related to 
bed rest alone and are compounded by the effects of acute 
illness; the cortisol: DHEAS is likely to be one of these 
mediators.  
As described above the development of sarcopenia is 
positively related to oxidative stress [32] and 
inflammatory insults [30, 31]. Systemic markers of 
inflammation rise acutely with acute illness and stressor 
events and may act to potentiate acute loss of muscle mass 
and function via this mechanism [80]. This could be via a 
direct effect on atrogene levels, or induction of 11βHSD1 
[57]. MaFbx and MuRF1 upregulation have been 
implicated in muscle atrophy; rodent models of sepsis 
induced by caecal ligation and puncture have been 
demonstrated to lead to increases of MaFbx and MuRF1 
mRNA levels [72]. These two atrogenes are ubiquitin 
ligases involved in the ubiquitin proteasome system 
(UPS); multiple inflammatory disease states have been 
demonstrated to be associated with increased levels of 
MAFbx and MuRF1 as well as components of the UPS. 
Further research in human studies is warranted to better 
evaluate these pathways in relation to inflammation [81].  
 
Intensive Care Unit-Acquired Weakness (ICU-AW) – 
part of a spectrum? 
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Intensive Care Unit-Acquired Weakness (ICU-AW) is a 
recognised complication following admission to the 
Intensive Care Unit (ICU). ICU-AW is an all-
encompassing term including critical illness myopathy 
(CIM), critical illness polyneuropathy (CIP) and critical 
illness neuromyopathy (CINM) [82]. Prolonged lengths 
of stay in the ICU are associated with increased loss of 
quadriceps muscle mass, suggesting that early 
intervention in this group of patients might help to 
conserve muscle mass [83]. 
The presences of sepsis or Systemic Inflammatory 
Response Syndrome (SIRS) criteria are known risk 
factors of ICU-AW. Local inflammation is found in ICU-
AW, although specificity is unknown. Fourteen studies 
examining the presence of inflammatory cells within 
human muscle biopsies demonstrated a positive finding in 
25% of cases (95% CI 18-34) [82]. One study assessed for 
the presence of cytokines in muscle biopsies taken from 
30 patients with ICU-AW; muscle biopsies from two ICU 
patients without ICU-AW were used as controls. The 
presence of TNFα (90% vs. 0%) and IL-10 (96% vs. 0%) 
was found to be significantly higher in biopsies taken 
from patients with ICU-AW [84]. Multi-organ failure is 
also associated with accelerated muscle wasting, when 
compare to single organ failure [85].  
ICU-AW affects comparatively younger individuals 
than age-related sarcopenia, even though these patients 
may not have been exposed to multiple previous episodes 
of oxidative stress or inflammatory insults. However, age 
is a risk factor for ICU-AW, a USA study reported a mean 
age of 59.73 years in those with ICU-AW compared to 
49.98 in those without [86]. Frail older adults are known 
to be at an increased risk of adverse outcomes following 
ICU admission and are often prevented from ICU 
admission to avoid unnecessary burden and harm [87]. It 
may be that ICU-AW would be catastrophic to this group 
of patients, presuming they survived the admission itself. 
ICU-AW may be related to the acute loss of muscle mass 
and muscle function experienced by older adults 
following hospitalisation or may be part of a spectrum of 
the same condition [88]. Figure 1 depicts our proposed 
model of the relationship between vulnerability and acute 
loss of muscle mass and function.  
 
 
 
 
 
Figure 1. Acute sarcopenia as part of a spectrum of acute muscle wasting disorders.  This 
schematic demonstrates the relationship between underlying predisposing factors and 
precipitating factors resulting in acute sarcopenia or acute muscle wasting. Physiologically fit 
adults who are immunocompetent may experience significant muscle wasting in the context of 
a critical illness necessitating admission to the intensive care unit. Conversely, frail older adults 
with immunosenescence may develop acute sarcopenia following a seemingly minor 
physiological stressor event such as a mild infection or short periods of bed rest. 
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Acute sarcopenia 
 
Acute sarcopenia: a proposed concept 
 
Current available research suggests that hospital 
admission is likely to have a negative impact upon muscle 
mass and muscle function [89]. This leads to overall 
worse outcomes, in terms of increased lengths of hospital 
stay, increased rehabilitation needs and increased 
discharge of patients to institutional care [16, 17]. We 
hypothesise that this is due to a combination of muscle 
disuse [18], endocrine dysregulation [90] and acute 
inflammatory burden [82]; these effects are likely to be 
compounded by age and previous cumulative insult [69]. 
In order to meet criteria for acute sarcopenia, rapid 
reductions in muscle mass and muscle function should be 
demonstrated; this requires that measurements of muscle 
mass and muscle function are available either pre-illness 
or during early stages of an illness.  
We define acute sarcopenia as changes in muscle 
mass and muscle function within 28 days of a significant 
physiological stressor event, such as an acute illness, 
surgery, trauma or burns [15, 90], sufficient to newly meet 
criteria for sarcopenia using previously defined cut-off 
points [1–3]. However, changes in muscle mass and 
function that are significant but that do not meet criteria 
for sarcopenia may have negative long-term 
consequences; further research is necessary to evaluate 
this [15].  Additionally, there may be an acute-on-chronic 
phenotype in some individuals; older adults who have 
sarcopenia may develop sarcopenia following an acute 
illness [1]. 
As a specific example, sepsis is a life-threatening 
condition characterised by the presence of infection 
associated with organ dysfunction. Survivors of severe 
sepsis are at an increased risk of developing new cognitive 
impairment or functional disability long-term [91].  Sepsis 
is associated with an acute upsurge in inflammatory 
markers and acute decline in muscle function [92]; this 
may impact upon the individual long-term. However, 
surgery, trauma and burns [93] are also associated with 
endocrine dysregulation and acute inflammatory burden 
and may similarly impact upon muscle mass and muscle 
function. Conversely, a frail older adult may be at 
increased risk of loss of muscle mass or function 
following a relatively minor illness due to a reduced 
immune response (immunosenescence) (see Fig. 1); 
immunosenescence affects an individual’s ability to 
overcome an infection or injury and may lead to sustained 
effects [94]. Altered neutrophil migratory dynamics for 
example occurring as part of ageing, lead to increased 
tissue damage from excess release of neutrophil elastase 
and resultant inflammation [95]. This in turn will 
contribute to muscle loss and frailty. 
 
Figure 2. Proposed disease trajectories associated with sarcopenia. This diagram 
demonstrates proposed trajectories associated with the development of sarcopenia over time. 
The green line demonstrates expected changes of muscle mass and function associated with 
healthy ageing; there may be some inevitable loss of muscle mass and function but not to such 
an extent as to cause detriment. The blue line demonstrates the development of chronic 
sarcopenia over time. The red line demonstrates our proposed model of how episodes of acute 
sarcopenia can potentially lead to the development of chronic sarcopenia over time. 
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As described, chronic age-related sarcopenia is 
associated with progressive decline over time secondary 
to an accumulation of insults [1]. We hypothesise that 
acute sarcopenia secondary to hospitalisation is associated 
with an acute rapid decline in muscle mass and muscle 
function. This may be partially recovered after discharge 
from hospital and recovery from illness, but may not 
return to pre-illness baseline [15]. This may lead to more 
rapid decline in muscle mass and function, resulting in 
chronic sarcopenia (see Fig. 2).  
Identifying risk factors for acute sarcopenia may be 
important in preventing these long-term sequelae. Risk 
factors are likely to include, but not be confined to 
conditions that lead to endocrine dysregulation, increased 
inflammatory state and/or result in reductions in mobility; 
delirium [96], sleep disturbance [97], chronic cognitive 
impairment [98] and acute and chronic psychological 
stress [99], along with malnutrition (reduced protein 
intake) [100] are potential ameliorators (see Fig. 3).   
 
 
 
 
Figure 3. Potential effectors of "acute sarcopenia" secondary to hospitalisation.  There are likely to be 
multiple potential factors that can increase an individual’s likelihood of developing acute sarcopenia. Some 
of these are person-specific factors that lead to an increased predisposition to developing this condition; others 
relate to the stressor event itself. Many of these effectors are potentially amenable to prevention or 
intervention. 
 
However, long-term data relating to outcomes 
following episodes of acute loss of muscle mass and 
function are currently lacking. There is some evidence 
that reduced signalling through anabolic pathways is of 
benefit with regards to reducing cancer risk and increasing 
longevity. Clearly, during acute illness upregulation of 
catabolic pathways helps to produce energy to overcome 
illness. Loss of muscle mass and function may be a trade-
off of this. Further research is needed in the form of 
observational studies and subsequent translational studies 
to assess potential targets and long-term risk from 
treatments.  
 
Acute sarcopenia: potential prevention strategies and 
treatments 
 
Physical activity interventions 
 
During hospital admission bed rest should be minimalised 
where possible [101]. This has wider health benefits 
beyond effect on muscle function, as bed rest is associated 
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with increased risk of pressure ulcers [102], venous 
thromboembolism [103], pneumonia [104] and 
constipation [105]. Although the association between bed 
rest and adverse outcomes has been reported for several 
decades [106, 107], hospital inpatients often remain 
reclined to bed in clinical practice [101]. This can partially 
be explained by staff reluctance to allow early 
mobilisation due to an increased risk of falls leading to 
traumatic brain injury, fracture or other injury [108]. This 
may compound the problem, as declines in muscle mass 
and function lead to increased risk of falls [5].  
There is increasing evidence that early mobilisation 
and intensive physical activity regimes can help to 
improve outcomes. A recently published trial involving 
92 non-delirious older medical inpatients demonstrated 
increased mobility at one month follow-up in those 
randomised to an inpatient mobility program compared to 
those who received usual care; no differences in ADL 
performance were reported [109]. A previous systematic 
review of exercise interventions for hospitalised older 
adults also found that the impact on ADL performance 
was unclear, but reported a small but important reduction 
in length of hospital stay and overall costs [110]. In the 
case of elective admissions, prehabilitation may be 
considered in the form of increased physical activity prior 
to admission. A randomised control trial of prehabilitation 
vs. rehabilitation in patients undergoing colorectal 
surgery demonstrated similar complication rates between 
the two groups but a significantly improved 6 minute 
walking test (6MWT) in the prehabilitation group at eight 
week follow-up [111]. 
Resistance exercise training in combination with 
moderate aerobic exercise have been shown to be 
beneficial in improving muscle mass and function in 
chronic sarcopenia [112]. Resistance exercise training is 
likely to be beneficial in the prevention and treatment of 
acute sarcopenia, in combination with aerobic exercise, 
however there are likely to be limitations in the extent that 
this can be tolerated during the acute illness. The optimum 
duration and intensity of physical activity to treat or 
prevent acute sarcopenia is currently unknown and is an 
important area for future research.  
 
Nutritional interventions 
 
Nutritional interventions have been trialled in chronic 
sarcopenia and there is increasing evidence that older 
adults have higher protein requirements than younger 
adults, with further increased requirements during acute 
illness [113]. Leucine intake is particularly important 
[114]. Only 5% leucine is metabolised to β-hydroxy-β-
methylbutyrate (HMB), thus direct administration of 
HMB may provide a more efficient alternative [115]. 
HMB administration prevents loss of lean leg mass in 
healthy older adults during bed rest [116] and has recently 
been demonstrated to reduce post-discharge mortality in a 
hospitalised population [117]. Protein supplementation 
can be implemented in the acute care setting alongside 
exercise interventions or alone, where early mobilisation 
is not possible [118].  
There are clear health benefits for promotion of 
physical activity and nutritional optimisation. However, 
further research is needed to clarify appropriate dosages, 
duration, intensity and timing that provide economic as 
well as individual benefits.  
 
Neuromuscular Electrical Stimulation (NMES) 
 
Neuromuscular Electrical Stimulation (NMES) involves 
the application of electrical current to stimulate muscular 
contraction and has been trialled in situations where 
mobilisation is not possible, such as in the ICU setting. A 
recent randomised controlled trial involving critically ill 
patients following cardiothoracic surgery demonstrated 
no effect of NMES applied bilaterally to quadriceps on 
muscle layer thickness, although patients regained muscle 
strength faster than the control group. The mean age in the 
NMES group was 63.3, compared to 69.7 in the control 
group [89]. Conversely, a study using NMES applied 
unilaterally significantly prevented reductions in muscle 
fibre cross-sectional area compared to biopsies taken from 
the control quadriceps. The mean age of patients in this 
study was 70 [119]. NMES is, therefore, a potential 
strategy to prevent targeted muscle atrophy and loss of 
muscle strength, but is less feasible at preventing loss of 
total skeletal muscle. 
 
Pharmacological therapies 
 
Novel pharmacological agents for treatment of sarcopenia 
include calorie restriction mimetics (CRMs) and exercise 
mimetics (EMs); these are phytochemicals such as 
resveratrol with antioxidant and regenerative properties 
that partially mimic the molecular pathways leading to the 
favourable effects of calorie restriction and physical 
exercise [120]. If proven beneficial, these may also 
provide benefit in the acute care setting in preventing 
acute loss of muscle mass and function. 
Recombinant growth hormone administration has 
previously been trialled with conflicting results. Growth 
hormone supplementation can increase skeletal muscle 
mass, but this is rarely accompanied by improved muscle 
strength and side-effects of this treatment are prevalent in 
older adults [121]. Testosterone supplementation to older 
men can increase muscle mass and muscle function [122, 
123] but is associated with significant increased adverse 
events including increased rates of prostate cancer and 
measured Prostate Specific Antigen (PSA) levels [124]. 
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Trials of supplementation with the androgen DHEA are 
extensive and results are contradictory. A recent 
systematic review reported that 5 out of 7 eligible studies 
showed improvement in single aspects of muscle 
function, such as grip strength or leg extensor strength, 
though only 1 showed improvement in a composite score 
of muscle strength [125]. Benefits of DHEA for 
sarcopenic adults remain to be established. 
 
Conclusions 
 
Acute sarcopenia secondary to hospital admission is 
hypothesised to be a related but distinct condition from 
chronic age-related primary sarcopenia. Acute illness or 
surgery lead to an acutely heightened inflammatory 
burden, which, coupled with reduced physical activity and 
muscle disuse, can lead to a reduction in muscle mass and 
function. The natural history of this condition needs 
further evaluation, including factors that affect rate and 
extent of development of this condition and long-term 
outcomes. 
It is unclear to what extent acute sarcopenia differs 
from chronic age-related sarcopenia in terms of biological 
and structural changes, physical phenotyping and long-
term outcomes. Further research is needed on this subject, 
initially to demonstrate the association between 
hospitalisation, acute illness or surgery and sarcopenia 
and, subsequently, to examine long-term outcomes and 
the effect of early interventions including physical 
therapy, nutritional supplementation or using novel 
therapeutic targets. In-vivo physiology and muscle biopsy 
studies will be vital in assessing mechanisms driving 
acute sarcopenia.  
Acute sarcopenia should be considered as a separate 
entity to chronic age-related sarcopenia, much in the same 
way that acute kidney injury is considered a separate 
disease to chronic kidney disease. The same criteria may 
be met for the two conditions, but it is the timing and 
natural history of the conditions that differ. However, 
considering the analogy above, there are likely to be 
overlap between the two conditions, with chronic 
sarcopenia being a possible risk factor for acute 
sarcopenia and the development of acute sarcopenia 
potentially increasing the long-term risk of chronic 
sarcopenia.  
The presence of low muscle mass and function during 
acute illness is associated with increased health economic 
costs in terms of increased length of hospital stay, 
rehabilitation costs and the need for institutional care or 
social care on discharge. Preventing acute sarcopenia will 
have wider economic benefits as well as individual benefit 
to patients. 
Initial research should determine the feasibility of 
conducting research on this condition in the acute care 
setting. The aim is that observational studies should be 
conducted within the next five years to include evaluation 
of histological changes and biological mechanisms. Focus 
on specific postulated risk factors, such as delirium will 
guide future treatment. Interventional studies involving 
nutritional, physical activity and other interventions 
should continue concurrently with assessment of general 
health and economic benefits. Prevention and early 
treatment of acute sarcopenia may help to prevent older 
adults from meeting criteria for sarcopenia in the long-
term. 
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